Pharmaceutical supplier EBOS Group has delivered a record net profit after tax of $149.6 million, up 12.2 per cent over the previous year, reflecting a year of strong organic growth combined with the added benefit of strategic acquisitions.

Group revenue remained stable at $7.6 billion, while earnings per share grew by 12.1 per cent.

“We are pleased to once again report strong financial results. We have delivered underlying, constant currency EBITDA growth slightly ahead of our guidance to the market,” said EBOS chief executive John Cullity.

“During the 2018 financial year we have fully transitioned HPS into the Group, further expanding our position in the Institutional Healthcare market.”

The company also acquired a strategic 14.1 per cent shareholding in MedAdvisor Ltd, and Australian digital medication management company in October 2017, and acquired one of New Zealand’s leading footcare consumer brands, Gran’s Remedy, in March 2018, which is manufactured and sold in New Zealand.

Black Hawk, EBOS’ animal care brand, performed ahead of expectations, according to Cullity, who noted the brand was receiving strong support from New Zealand retail partners and customers, leading to an 11.3 per cent growth in EBDITA for the year for the category.

The New Zealand Healthcare operations delivered a strong performance, with revenue increasing 6.2 per cent and EBITDA increasing 4.6 per cent.

The group noted its strong financial position, and remains confident of further profit growth into FY19 on an underlying, constant currency basis.